Investigational drug · Phase 3
CYB003
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Major Depressive Disorder, Major Depressive Disorder (MDD), Depression in Adults.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
5
Any phase or sponsor naming "CYB003"
First trial start
2024
Dec 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CYB003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder
- Major Depressive Disorder (MDD)
- Depression in Adults
- Depression - Major Depressive Disorder
- Depression Disorders
- Depression Disorder
- Depression
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "CYB003" as an intervention, largest first.
- Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)Pivotal-lookingEnrolling by invitation
Cybin IRL LimitedIndustry
NCT06605105 · 468 participants (planned) · Start Jul 18, 2025 · Primary completion Jun 6, 2028
Drug: CYB003 · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Glendale, California; La Jolla, California · 49 sites in all
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPivotal-lookingRecruiting
Cybin IRL LimitedIndustry
NCT06793397 · 330 participants (planned) · Start Dec 10, 2025 · Primary completion Jun 7, 2027
Drug: CYB003 · For: Major Depressive Disorder (MDD); Depression in Adults; Depression - Major Depressive Disorder and 3 more
Sites: Birmingham, Alabama; Gilbert, Arizona; Little Rock, Arkansas · 79 sites in all
- "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"Pivotal-lookingCompleted
Cybin IRL LimitedIndustry
NCT06564818 · 223 participants · Start Dec 17, 2024 · Primary completion Sep 4, 2026
Drug: CYB003; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Tucson, Arizona; Bellflower, California · 45 sites in all
Cybin IRL LimitedIndustry
NCT05385783 · 57 participants · Start Aug 2, 2022 · Primary completion Oct 16, 2023
Drug: CYB003; Placebo · For: Major Depressive Disorder
Sites: Atlanta, Georgia; Decatur, Georgia; Eatontown, New Jersey
- A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and AnxietyRecruiting
Ohio State UniversityAcademic, hospital or other
NCT06820723 · 40 participants (planned) · Start Nov 1, 2026 · Primary completion Nov 2028
Drug: CYB003; Placebo · For: Depression; Anxiety; Major Depressive Disorder
Sites: Columbus, Ohio
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Major Depressive Disorder
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- BHV-7000Phase 36 trials
Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder
- NBI-1065845TAK-653, OsavampatorPhase 35 trials
Neurocrine Biosciences · Major Depressive Disorder
- CYM-53093Navacaprant, NMRA-335140Phase 34 trials
Neumora Therapeutics, Inc. · Major Depressive Disorder, Major Depressive Episode Associated With Bipolar II Disorder
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- PsilocybinCOMP360Phase 34 trials
COMPASS Pathways · Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.